Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer
31
0
2023-11-3 17:17
Progressive descending facial nerve paralysis in amyloidosis
Fragile X-associated tremor or ataxia syndrome
Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab
Always use containment morcellation bags
The Carbon Cost of Healthcare
Efficacy and safety of treating alopecia areata with ritlecitinib
Stridor from birth indicates congenital upper airway obstruction
Biosimilar adalimumab for patients with active rheumatoid arthritis
0 bullet chats
Please Sign In first
Unauthorized reproduction is prohibited
Dr James Harding presents the findings of their paper, published in The Lancet Oncology on 2 June 2023: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZONBTC-01): a multicentre, single-arm, phase 2b study.
Comments 0
Please to post a comment~
Loading...
Related Suggestion